MTOR and Kaposi's sarcoma: However, the use of mTOR inhibitors in this indication has only been validated in the context of non-melanoma skin cancers and Kaposi sarcoma, moreover these treatments have lower immunosuppressive effects than CNI and can lead to the increase in proteinuria.